Trials / Completed
CompletedNCT05995275
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
A Randomised, Placebo-Controlled, Dose-Ranging, Observer-Blind Phase 1/2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of mRNA-1769 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 351 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1769 | Sterile liquid for injection |
| OTHER | Placebo | 0.9% sodium chloride injection (normal saline) |
Timeline
- Start date
- 2023-08-15
- Primary completion
- 2025-07-08
- Completion
- 2025-07-08
- First posted
- 2023-08-16
- Last updated
- 2025-07-16
Locations
12 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05995275. Inclusion in this directory is not an endorsement.